Skip to main content

Table 3 Differences from baseline in efficacy variables at different time points (FAS)

From: Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial

Variable

Treatment group (n = 177)

Control group (n = 180)

P value

Migraine attacks

 4 W

2.66 ± 1.40

2.66 ± 1.20

0.864

 8 W

2.04 ± 1.30

1.93 ± 1.19

0.153

 12 W

1.57 ± 1.46

1.42 ± 1.12

0.460

 Follow-up period

1.37 ± 1.30

1.55 ± 1.30

0.398

Migraine days

 4w

2.98 ± 1.74

2.91 ± 1.41

0.994

 8w

2.25 ± 1.72

2.13 ± 1.42

0.588

 12 w

1.73 ± 1.78

1.58 ± 1.34

0.093

 Follow-up period

1.46 ± 1.55

1.68 ± 1.50

0.001*

VAS scores

 4w

4.94 ± 1.26

4.79 ± 1.14

0.990

 8w

4.34 ± 1.31

4.22 ± 1.23

0.404

 12 w

3.58 ± 1.05

3.26 ± 1.47

0.141

 Follow-up period

3.87 ± 1.25

3.85 ± 1.41

0.852

Total Duration(h)

 4w

19.70 ± 19.69

19.18 ± 19.24

0.009*

 8w

14.68 ± 21.83

12.41 ± 14.41

0.753

 12 w

11.71 ± 24.83

8.69 ± 12.89

0.526

 Follow-up period

7.55 ± 13.76

7.31 ± 11.74

0.140

Analgesic consumption (times)

 4w

0.96 ± 1.30

1.01 ± 1.59

0.229

 8w

0.86 ± 1.65

0.76 ± 1.42

0.862

 12w

0.70 ± 1.52

0.51 ± 1.07

0.360

 Follow-up period

0.51 ± 1.37

0.41 ± 1.29

0.652

  1. Note: *P < 0.05 for data comparison between groups after treatment